ACADIA Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ACAD and other ETFs, options, and stocks.

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. 

CEO
Catherine Owen Adams
CEOCatherine Owen Adams
Employees
654
Employees654
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1993
Founded1993
Employees
654
Employees654

ACAD Key Statistics

Market cap
3.59B
Market cap3.59B
Price-Earnings ratio
15.82
Price-Earnings ratio15.82
Dividend yield
Dividend yield
Average volume
2.88M
Average volume2.88M
High today
$21.53
High today$21.53
Low today
$21.04
Low today$21.04
Open price
$21.21
Open price$21.21
Volume
940.57K
Volume940.57K
52 Week high
$26.65
52 Week high$26.65
52 Week low
$13.40
52 Week low$13.40

ACAD News

TipRanks 4d
Acadia Pharmaceuticals price target lowered to $29 from $35 at Deutsche Bank

Deutsche Bank lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $29 from $35 and keeps a Buy rating on the shares. Elevate Your Investing Str...

TipRanks 5d
ACADIA Pharmaceuticals: Growth Potential Despite Setbacks with Promising Pipeline and Core Business Expansion

TD Cowen analyst Ritu Baral maintained a Buy rating on ACADIA Pharmaceuticals today and set a price target of $35.00. Elevate Your Investing Strategy: Take adva...

Benzinga 5d
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Acadia Pharmaceuticals Inc. ACAD released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbe...

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Analyst ratings

63%

of 19 ratings
Buy
63.2%
Hold
31.6%
Sell
5.3%

More ACAD News

TipRanks 5d
Positive Outlook for ACADIA Pharmaceuticals Despite Setbacks: Buy Rating Justified

Ami Fadia, an analyst from Needham, reiterated the Buy rating on ACADIA Pharmaceuticals. The associated price target was lowered to $28.00. Elevate Your Investi...

TipRanks 5d
Balanced Hold Rating for ACADIA Pharmaceuticals Amid Trial Setback and Growth Potential

Analyst Sean Laaman of Morgan Stanley maintained a Hold rating on ACADIA Pharmaceuticals, retaining the price target of $24.00. Elevate Your Investing Strategy:...

People also own

Based on the portfolios of people who own ACAD. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.